Skip to content

MDMA: all studies

Page 63 of 347: studies 621 to 630 of 3,461, newest first. Back to the MDMA overview

Research

Sexual Ecstasy Scale: Conceptualizations and measurement

International Journal of Transpersonal Studies September 1, 2019

This article describes the development of the Sexual Ecstasy Scale, an instrument designed to measure the specific features that emerge when sexual arousal is the trigger for an ecstatic experience. Drawing from descriptions of features of sexual ecstasy in the phenomenological literature, the authors generated an initial survey of 31 items. In Study 1, the survey was completed by a wide...

'Never drop without your significant other, cause that way lies ruin': The boundary work of couples who use MDMA together.

International Journal of Drug Policy September 1, 2019 Katie Anderson, Paula Reavey, Zoë Boden 10 citations

MDMA has a variety of pro-social effects, such as increased friendliness and heightened empathy, yet there is a distinct lack of research examining how these effects might intertwine with a romantic relationship. This article seeks to compensate for this absence and explore heterosexual couples' use of MDMA through the lens of the boundaries they construct around these experiences. Three couple...

MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials.

Psychopharmacology September 1, 2019 Michael C Mithoefer, Allison A. Feduccia, Lisa Jerome et al. 364 citations Retracted

Posttraumatic stress disorder is a prevalent mental health condition with substantial impact on daily functioning that lacks sufficient treatment options. Here we evaluate six phase 2 trials in a pooled analysis to determine the study design for phase 3 trials of MDMA-assisted psychotherapy for PTSD. Six randomized, double-blind, controlled clinical trials at five study sites were conducted...

DOI: 10.1007/s00213-019-05249-5 (opens in new tab) Full text (opens in new tab) MDMA-Assisted Psychotherapy Posttraumatic stress disorder MDMA Alongside Therapy Active MDMA +7

Differential role of dose and environment in initiating and intensifying neurotoxicity caused by MDMA in rats

BMC Pharmacology and Toxicology August 5, 2019 Ibrahim M. Shokry, Connor J. Shields, John J. Callanan et al.

Background MDMA causes serotonin (5-HT) syndrome immediately after administration and serotonergic injury in a few days or weeks. However, a serotonin syndrome is not always followed by serotonergic injury, indicating different mechanisms responsible for two adverse effects. The goal of present study was to determine causes for two adverse events and further test that dose and environment have...

DOI: 10.1186/s40360-019-0326-6 (opens in new tab) Full text (opens in new tab) MDMA Toxicity Serotonin syndrome Serotonergic injury Hypothermia +6

Culturally informed research design issues in a study for MDMA-assisted psychotherapy for posttraumatic stress disorder

Journal of Psychedelic Studies July 30, 2019 Monnica T. Williams, Sara Reed, Ritika Aggarwal 87 citations

Recent research suggests that psychedelic drugs can be powerful agents of change when utilized in conjunction with psychotherapy. Methylenedioxymethamphetamine (MDMA)-assisted psychotherapy has been studied as a means of helping people overcome posttraumatic stress disorder, believed to work by reducing fear of traumatic memories and increasing feelings of trust and compassion toward others,...

Intersectional insights from an MDMA-assisted psychotherapy training trial: An open letter to racial/ethnic and sexual/gender minorities

Journal of Psychedelic Studies July 24, 2019 Terence H. W. Ching

The road to the current psychedelic renaissance in research on ±3,4-methylenedioxymethamphetamine (MDMA) – the active ingredient of the drug Ecstasy – for addressing treatment-resistant post-traumatic stress disorder has been fraught with political and academic bias, as well as cultural stigma among underserved populations, all of which serve as barriers to minority inclusion and participation....

First study of safety and tolerability of 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy in patients with alcohol use disorder: preliminary data on the first four participants.

BMJ Case Reports July 15, 2019 Ben Sessa, Chloe Sakal, Steve O’Brien et al. 55 citations

We present the preliminary data in an ongoing open-label safety and tolerability proof of concept study exploring the potential role for 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy in treating patients with alcohol use disorder. At this stage, seven participants have completed the full 8-week MDMA-assisted psychotherapy course, including two therapy sessions each with MDMA....

Risk intentions following pill test scenarios are predicted by MDMA use history and sensation seeking: A quantitative field study at an Australian music festival.

Drug and Alcohol Review July 2019 Ross C Hollett, Natalie Gately

Most Australian Governments have resisted supporting formal pill testing (drug checking) at music festivals. With limited knowledge available regarding post-pill test substance use behaviour, we aimed to understand risk behaviour within three pill test scenarios by determining the individual factors which predict subsequent risky or risk reduction intentions. Music festival attendees (N = 276)...

Concurrent Inhibition of Vesicular Monoamine Transporter 2 Does Not Protect Against 3,4-Methylenedioxymethamphetamine (Ecstasy) Induced Neurotoxicity.

Toxicological sciences : an official journal of the Society of Toxicology July 1, 2019 Aram B Cholanians, Andy V Phan, Serrine S. Lau et al.

3, 4-Methylenedioxymethamphetamine (MDMA) is a hallucinogenic amphetamine derivative. The acute effects of MDMA are hyperthermia, hyperactivity, and behavioral changes, followed by long-term serotonergic neurotoxicity in rats and primates. However, the underlying mechanisms of MDMA neurotoxicity remain elusive. We reported that pretreatment of rats with Ro 4-1284, a reversible inhibitor of the...

Cognitive Effects of MDMA in Laboratory Animals: A Systematic Review Focusing on Dose.

Pharmacological Reviews July 1, 2019 Madeline M. Pantoni, Stephan G Anagnostaras

±3,4-Methylenedioxymethamphetamine (MDMA) is a synthetic, psychoactive drug that is primarily used recreationally but also may have some therapeutic value. At low doses, MDMA produces feelings of relaxation, empathy, emotional closeness, and euphoria. Higher doses can produce unpleasant psychostimulant- and hallucinogen-like adverse effects and therefore are usually not taken intentionally....

DOI: 10.1124/pr.118.017087 (opens in new tab) Full text (opens in new tab) Animals, laboratory N-methyl-3,4-methylenedioxyamphetamine Cognition Dose-response relationship, drug